spacer
home > ict > summer 2019 > the long and short of cro selection
PUBLICATIONS
International Clinical Trials

The Long and Short of CRO Selection




Over recent years, there has been a progression in companies outsourcing their pharmacovigilance to CROs that either specialise in this area or as part of the suite of services they offer. It is clear that there is much work to be done before deciding on which CRO to choose, and there are several factors that need to be considered by the sponsor or licence holder.

Once the decision is taken to outsource, because each company/sponsor is unique, the demands and requirements of the CRO will differ, and it is important to know it has the expertise for immediate and possible long-term needs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Graeme Ladds has worked in pharmacovigilance and medical services for the last 30 years, specialising in both global clinical development and postmarketing for a variety of large and small pharma companies in senior positions. For the last 16 years, Graeme has worked at his own CRO, PharSafer, engaging with clients worldwide and helping them gain licensure and postmarketing for many countries. He also teaches and trains in pharmacovigilance around the world for many companies and works for clients on many product acquisitions and sales (divestments).


Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement